AbbVie Gelecekteki Büyüme

Future kriter kontrolleri 5/6

AbbVie kazanç ve gelirin sırasıyla yıllık 28.1% ve 6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 28.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 442.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

28.1%

Kazanç büyüme oranı

28.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.7%
Gelir büyüme oranı	6.0%
Gelecekteki özkaynak getirisi	442.8%
Analist kapsamı	Good
Son güncelleme	25 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:4AB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	63,354	14,572	26,581	25,726	24
12/31/2025	59,082	11,969	24,922	23,702	27
12/31/2024	56,021	8,250	17,411	18,083	25
9/30/2024	55,533	5,081	15,623	16,511	N/A
6/30/2024	55,000	5,298	17,780	18,638	N/A
3/31/2024	54,403	5,951	21,891	22,686	N/A
12/31/2023	54,318	4,820	22,062	22,839	N/A
9/30/2023	55,138	6,471	24,729	25,514	N/A
6/30/2023	56,023	8,635	24,799	25,542	N/A
3/31/2023	56,741	7,535	23,520	24,228	N/A
12/31/2022	58,054	11,782	24,248	24,943	N/A
9/30/2022	57,819	13,343	21,921	22,590	N/A
6/30/2022	57,349	12,569	22,214	22,923	N/A
3/31/2022	56,725	12,407	22,047	22,808	N/A
12/31/2021	56,197	11,468	21,990	22,777	N/A
9/30/2021	55,169	7,465	21,677	22,556	N/A
6/30/2021	53,729	6,599	19,572	20,451	N/A
3/31/2021	50,195	5,092	17,789	18,650	N/A
12/31/2020	45,804	4,556	16,790	17,588	N/A
9/30/2020	40,650	7,324	15,327	16,009	N/A
6/30/2020	36,227	6,906	14,115	14,734	N/A
3/31/2020	34,057	8,395	13,552	14,122	N/A
12/31/2019	33,266	7,842	12,772	13,324	N/A
9/30/2019	32,867	3,232	12,929	13,441	N/A
6/30/2019	32,624	4,093	12,770	13,410	N/A
3/31/2019	32,647	5,333	13,173	13,799	N/A
12/31/2018	32,753	5,657	12,789	13,427	N/A
9/30/2018	32,187	7,531	11,922	12,619	N/A
6/30/2018	30,946	6,419	N/A	11,366	N/A
3/31/2018	29,612	6,352	N/A	10,503	N/A
12/31/2017	28,216	5,283	N/A	9,960	N/A
9/30/2017	27,273	6,615	N/A	8,917	N/A
6/30/2017	26,710	6,582	N/A	7,100	N/A
3/31/2017	26,218	6,278	N/A	7,015	N/A
12/31/2016	25,638	5,923	N/A	7,041	N/A
9/30/2016	25,242	6,048	N/A	7,463	N/A
6/30/2016	24,754	5,690	N/A	8,164	N/A
3/31/2016	23,777	5,448	N/A	8,078	N/A
12/31/2015	22,859	5,118	N/A	7,535	N/A
9/30/2015	21,911	2,790	N/A	4,994	N/A
6/30/2015	20,986	2,064	N/A	4,625	N/A
3/31/2015	20,437	1,802	N/A	4,510	N/A
12/31/2014	19,960	1,765	N/A	3,549	N/A
9/30/2014	19,619	3,686	N/A	5,372	N/A
6/30/2014	19,258	4,144	N/A	5,384	N/A
3/31/2014	19,024	4,114	N/A	5,704	N/A
12/31/2013	18,790	4,102	N/A	6,267	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 4AB 'nin tahmini kazanç büyümesi (yıllık 28.1% ) tasarruf oranının ( 1% ) üzerindedir.

Kazançlar ve Piyasa: 4AB şirketinin kazançlarının (yıllık 28.1% ) German pazarından (yıllık 20.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 4AB şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 4AB şirketinin gelirinin (yıllık 6% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 4AB şirketinin gelirinin (yıllık 6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 4AB 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 442.8 %).

AbbVie Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter dividend of US$1.64 announced

Investor sentiment deteriorates as stock falls 16%

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

Third quarter 2024 earnings released: EPS: US$0.88 (vs US$1.00 in 3Q 2023)

AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Upcoming dividend of US$1.55 per share

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Second quarter dividend of US$1.55 announced

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold €11m worth of stock

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: US$0.77 (vs US$1.14 in 2Q 2023)

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings released: EPS: US$0.77 (vs US$0.13 in 1Q 2023)

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin